AR101286A1 - Formulación en forma de tableta de un inhibidor de c-met - Google Patents
Formulación en forma de tableta de un inhibidor de c-metInfo
- Publication number
- AR101286A1 AR101286A1 ARP150102336A ARP150102336A AR101286A1 AR 101286 A1 AR101286 A1 AR 101286A1 AR P150102336 A ARP150102336 A AR P150102336A AR P150102336 A ARP150102336 A AR P150102336A AR 101286 A1 AR101286 A1 AR 101286A1
- Authority
- AR
- Argentina
- Prior art keywords
- tablet
- granular phase
- triazin
- quinolin
- imidazo
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- LIOLIMKSCNQPLV-UHFFFAOYSA-N 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1C1=NN2C(CC=3C=C4C=CC=NC4=CC=3)=CN=C2N=C1 LIOLIMKSCNQPLV-UHFFFAOYSA-N 0.000 abstract 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 abstract 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 abstract 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 abstract 2
- 239000008108 microcrystalline cellulose Substances 0.000 abstract 2
- 229940016286 microcrystalline cellulose Drugs 0.000 abstract 2
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 abstract 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 abstract 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
- 229930195725 Mannitol Natural products 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 abstract 1
- 235000019359 magnesium stearate Nutrition 0.000 abstract 1
- 239000000594 mannitol Substances 0.000 abstract 1
- 235000010355 mannitol Nutrition 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 abstract 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/06—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of pills, lozenges or dragees
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462028865P | 2014-07-25 | 2014-07-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR101286A1 true AR101286A1 (es) | 2016-12-07 |
Family
ID=53762251
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150102336A AR101286A1 (es) | 2014-07-25 | 2015-07-23 | Formulación en forma de tableta de un inhibidor de c-met |
Country Status (31)
| Country | Link |
|---|---|
| US (5) | US10085993B2 (enExample) |
| EP (2) | EP3848376A1 (enExample) |
| JP (3) | JP6770946B2 (enExample) |
| KR (2) | KR20230136693A (enExample) |
| CN (2) | CN115364061A (enExample) |
| AR (1) | AR101286A1 (enExample) |
| AU (4) | AU2015293539A1 (enExample) |
| CA (1) | CA2954840A1 (enExample) |
| CL (1) | CL2017000180A1 (enExample) |
| CO (1) | CO2017000586A2 (enExample) |
| DK (1) | DK3172209T3 (enExample) |
| EA (2) | EA039220B1 (enExample) |
| EC (1) | ECSP17011672A (enExample) |
| ES (1) | ES2857523T3 (enExample) |
| FR (1) | FR22C1058I2 (enExample) |
| GT (1) | GT201700007A (enExample) |
| HU (2) | HUE053346T2 (enExample) |
| IL (1) | IL250166B (enExample) |
| JO (1) | JO3618B1 (enExample) |
| MX (2) | MX379279B (enExample) |
| MY (1) | MY187276A (enExample) |
| NL (1) | NL301208I2 (enExample) |
| NO (1) | NO2022058I1 (enExample) |
| PE (1) | PE20170523A1 (enExample) |
| PH (1) | PH12017500121A1 (enExample) |
| PL (1) | PL3172209T3 (enExample) |
| PT (1) | PT3172209T (enExample) |
| SG (2) | SG11201700147SA (enExample) |
| SI (1) | SI3172209T1 (enExample) |
| TW (2) | TW202200148A (enExample) |
| WO (1) | WO2016012963A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2868202C (en) | 2012-04-03 | 2021-08-10 | Novartis Ag | Combination products with tyrosine kinase inhibitors and their use |
| DK3172209T3 (da) | 2014-07-25 | 2021-02-22 | Novartis Ag | Tabletformulering med 2-fluor-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamid |
| TWI736660B (zh) | 2016-08-10 | 2021-08-21 | 瑞士商赫孚孟拉羅股份公司 | 包含Akt蛋白質激酶抑制劑之醫藥組合物 |
| US11407735B2 (en) | 2019-05-16 | 2022-08-09 | Novartis Ag | Crystalline forms of N-[4-(Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide |
| JP7675071B2 (ja) * | 2019-10-24 | 2025-05-12 | ハンミ ファーマシューティカル カンパニー リミテッド | がん細胞の成長を阻害するアミド誘導体を含む医薬調製物およびそれを含有する医薬品 |
| WO2022007752A1 (zh) * | 2020-07-06 | 2022-01-13 | 苏州晶云药物科技股份有限公司 | 苯甲酰胺类化合物及其二盐酸盐的新晶型及其制备方法 |
| CN114853762A (zh) * | 2021-02-03 | 2022-08-05 | 四川科伦药物研究院有限公司 | 一种咪唑并三嗪类化合物的固体形式及其制备方法和用途 |
| CN118251220A (zh) * | 2022-01-19 | 2024-06-25 | 江苏奥赛康药业有限公司 | 一种包含嘧啶基团的三并环类化合物的组合物及其制备方法和应用 |
| WO2023249994A1 (en) * | 2022-06-22 | 2023-12-28 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| AU2023324893A1 (en) * | 2022-08-19 | 2025-03-13 | Mirati Therapeutics, Inc. | Adagrasib solid pharmaceutical compositions |
| WO2024206858A1 (en) | 2023-03-30 | 2024-10-03 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6762778B1 (en) | 1999-06-10 | 2004-07-13 | Dassault Systemes | Three dimensional graphical manipulator |
| CA2465565A1 (en) * | 2003-06-12 | 2004-12-12 | Warner-Lambert Company Llc | Pharmaceutical compositions of atorvastatin |
| EP1909777A2 (en) * | 2005-07-22 | 2008-04-16 | Myriad Genetics, Inc. | High drug load formulations and dosage forms |
| WO2007031933A2 (en) | 2005-09-12 | 2007-03-22 | Actelion Pharmaceuticals Ltd | Stable pharmaceutical composition comprising a pyrimidine-sulfamide |
| CA2563690C (en) | 2006-10-12 | 2014-10-07 | Pharmascience Inc. | Pharmaceutical compositions comprising intra- and extra- granular fractions |
| PL2497470T3 (pl) | 2006-11-22 | 2016-04-29 | Incyte Holdings Corp | Imidazotriazyny i imidazopirymidyny jako inhibitory kinazy |
| JP6022158B2 (ja) | 2008-05-21 | 2016-11-09 | インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ | ２−フルオロ−Ｎ−メチル−４−［７−（キノリン−６−イル−メチル）−イミダゾ［１，２−ｂ］［１，２，４］トリアジン−２−イル］ベンズアミドの塩及びそれを調製することに関する方法 |
| PT4066821T (pt) * | 2009-11-09 | 2025-06-03 | Wyeth Llc | Formulações de comprimidos de maleato de neratinib |
| JP5846647B2 (ja) | 2010-02-25 | 2016-01-20 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | アピキサバン製剤 |
| NZ603686A (en) * | 2010-05-21 | 2014-11-28 | Incyte Corp | Topical formulation for a jak inhibitor |
| WO2012006298A2 (en) | 2010-07-06 | 2012-01-12 | Janssen Pharmaceutica Nv | Formulation for co-therapy treatment of diabetes |
| RU2705095C2 (ru) | 2012-08-16 | 2019-11-05 | Новартис Аг | Комбинация ингибитора pik3 и ингибитора с-мет |
| DK3172209T3 (da) | 2014-07-25 | 2021-02-22 | Novartis Ag | Tabletformulering med 2-fluor-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamid |
-
2015
- 2015-07-22 DK DK15744702.0T patent/DK3172209T3/da active
- 2015-07-22 SI SI201531507T patent/SI3172209T1/sl unknown
- 2015-07-22 KR KR1020237031767A patent/KR20230136693A/ko not_active Ceased
- 2015-07-22 PL PL15744702T patent/PL3172209T3/pl unknown
- 2015-07-22 AU AU2015293539A patent/AU2015293539A1/en not_active Abandoned
- 2015-07-22 CN CN202210949714.1A patent/CN115364061A/zh active Pending
- 2015-07-22 EP EP20210458.4A patent/EP3848376A1/en not_active Withdrawn
- 2015-07-22 ES ES15744702T patent/ES2857523T3/es active Active
- 2015-07-22 PE PE2017000097A patent/PE20170523A1/es unknown
- 2015-07-22 CA CA2954840A patent/CA2954840A1/en active Pending
- 2015-07-22 SG SG11201700147SA patent/SG11201700147SA/en unknown
- 2015-07-22 EA EA201790259A patent/EA039220B1/ru unknown
- 2015-07-22 EA EA202191301A patent/EA202191301A1/ru unknown
- 2015-07-22 MX MX2017001177A patent/MX379279B/es unknown
- 2015-07-22 WO PCT/IB2015/055561 patent/WO2016012963A1/en not_active Ceased
- 2015-07-22 PT PT157447020T patent/PT3172209T/pt unknown
- 2015-07-22 MY MYPI2017700061A patent/MY187276A/en unknown
- 2015-07-22 CN CN201580052264.4A patent/CN106714784A/zh active Pending
- 2015-07-22 KR KR1020177004939A patent/KR102581121B1/ko active Active
- 2015-07-22 HU HUE15744702A patent/HUE053346T2/hu unknown
- 2015-07-22 EP EP15744702.0A patent/EP3172209B1/en active Active
- 2015-07-22 US US15/328,661 patent/US10085993B2/en active Active
- 2015-07-22 SG SG10201900648SA patent/SG10201900648SA/en unknown
- 2015-07-22 JP JP2017504062A patent/JP6770946B2/ja active Active
- 2015-07-23 AR ARP150102336A patent/AR101286A1/es unknown
- 2015-07-23 TW TW110109338A patent/TW202200148A/zh unknown
- 2015-07-23 TW TW104123937A patent/TWI724993B/zh active
- 2015-07-23 JO JOP/2015/0174A patent/JO3618B1/ar active
-
2017
- 2017-01-17 IL IL250166A patent/IL250166B/en active IP Right Grant
- 2017-01-20 PH PH12017500121A patent/PH12017500121A1/en unknown
- 2017-01-24 CO CONC2017/0000586A patent/CO2017000586A2/es unknown
- 2017-01-24 CL CL2017000180A patent/CL2017000180A1/es unknown
- 2017-01-25 GT GT201700007A patent/GT201700007A/es unknown
- 2017-01-25 MX MX2021000595A patent/MX2021000595A/es unknown
- 2017-02-24 EC ECIEPI201711672A patent/ECSP17011672A/es unknown
-
2018
- 2018-07-23 AU AU2018207947A patent/AU2018207947A1/en not_active Abandoned
- 2018-09-18 US US16/134,162 patent/US10596178B2/en active Active
-
2020
- 2020-02-07 AU AU2020200912A patent/AU2020200912B2/en active Active
- 2020-02-13 US US16/789,655 patent/US20210113569A1/en not_active Abandoned
- 2020-03-27 JP JP2020058164A patent/JP7002587B2/ja active Active
-
2021
- 2021-04-23 AU AU2021202500A patent/AU2021202500A1/en not_active Abandoned
- 2021-12-15 US US17/644,473 patent/US12208101B2/en active Active
- 2021-12-24 JP JP2021211526A patent/JP2022046659A/ja active Pending
-
2022
- 2022-12-06 FR FR22C1058C patent/FR22C1058I2/fr active Active
- 2022-12-16 NL NL301208C patent/NL301208I2/nl unknown
- 2022-12-16 NO NO2022058C patent/NO2022058I1/no unknown
- 2022-12-19 HU HUS2200054C patent/HUS2200054I1/hu unknown
-
2024
- 2024-12-16 US US18/982,128 patent/US20250339440A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR101286A1 (es) | Formulación en forma de tableta de un inhibidor de c-met | |
| IL288231A (en) | An inhibitor of jak1/2 or a pharmaceutical salt derived from it and an inhibitor of pi3k or a pharmaceutical salt derived from it, for use in the treatment of myelofibroblasts. | |
| AR113758A1 (es) | Proceso para la preparación de 6-(2-hidroxi-2-metilpropoxi)-4-(6-(6-((6-metoxipiridin-3-il)metil)-3,6-diazabiciclo[3.1.1]heptan-3-il)piridin-3-il)pirazolo[1,5-a]piridina-3-carbonitrilo | |
| MX2021002321A (es) | Nuevos metodos. | |
| IL268960A (en) | 7,6,5,4-Tetrahydroisoxazazole (4,5-c) Pyridin-3-ol (thip) for use in the treatment of broken x syndrome | |
| PH12017500287A1 (en) | Acid-addition salt of trk-inhibiting compound | |
| EP4389227A3 (en) | Valbenazine dosage regimen for the treatment of hyperkinetic movement disorders | |
| MX2017001540A (es) | Tabletas de rucaparib de dosificacion elevada. | |
| WO2015160975A3 (en) | Combination of a pi3k inhibitor with a bcl-2 inhibitor for use in the treatment of cancer | |
| MX2018016299A (es) | Derivados de imidazo[1,2-a]piridina, métodos para preparar los mismos y uso de los mismos. | |
| ECSP11011403A (es) | Derivado de benzodiazepina para el tratamiento de neoplasma hematopoyetico y leucemia | |
| MX2017007551A (es) | Derivado de dihidroindolizinona. | |
| BR112016026667A2 (pt) | comprimido oralmente desintegrante para administração de avanafil, métodos associados de fabricação e uso de um inibidor de pde v | |
| AR108500A1 (es) | Un análogo de trifluoroetil quinolina específico para usar en el tratamiento de apds | |
| ZA202200511B (en) | Ring-fused thiazolino 2-pyridones, methods for preparation thereof and their use in the treatment and/or prevention of tuberculosis | |
| MY195799A (en) | Pharmaceutical Formulations of Tropomyosin-Related Kinase (TRK) Inhibitors | |
| MX2017013103A (es) | Metodos para el tratamiento de trastornos cardiovasculares. | |
| CL2016001361A1 (es) | Regimen de dosificación para un inhibidor selectivo alfa-isomorfo de fosfatidilinositol 3-quinasa | |
| PH12018500579A1 (en) | Fungal keratitis prophylactic or therapeutic agent | |
| HK1232798A1 (en) | Orally disintegrating tablet of nabilone comprising mannitol-based granules | |
| MX2015009504A (es) | Composicion farmaceutica de desloratadina para ser administrada por via oral, para el tratamiento de enfermedades relacionadas con la histamina. | |
| AR099971A1 (es) | Forma de dosificación unitaria que comprende emtricitabina, tenofovir, darunavir y ritonavir y un comprimido monolítico que comprende darunavir y ritonavir | |
| HK1231763A1 (en) | Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |